GTx Initiates Phase I Clinical Trial for Its Second SARM Ostarine

GTx has initiated a Phase I clinical trial for ostarine, GTx's second selective androgen receptor modulator (SARM) compound to be tested in clinical trials.

The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of ostarine using a single ascending dose, double-blind, placebo-controlled design in healthy volunteers.

Ostarine is a nonsteroidal SARM that is designed to have positive anabolic effects without having an impact on the prostate and is being developed for andropause as well as other conditions associated with aging, such as sarcopenia. Sarcopenia is defined as the loss of muscle mass associated with aging leading to frailty and loss of independence.